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New information has prompted revision of the conceptual framework for con-
sidering the epidemiology and virology of viral hepatitis. The means are now at hand
to identify infections due to either Hepatitis A or B, as well as to implicate other
etiologic agents in hepatitis. Immunologic evidence of variation in the antigens
associated with Hepatitis B, and possibly in Hepatitis A, may explain some well
known epidemiologic phenomena and has important implications in immune serum
globulin prophylaxis. The ambiguous relationship of antigenemia and viremia in
Hepatitis B is explored in relation to the hepatitis hazard of blood products, to trials
of immune serum globulin, and to the potential role of the carrier-health worker
in hepatitis transmission. The emerging concept of non-parenteral transmission of
Hepatitis B is reviewed and future developments in the production of hepatitis
vaccines and in experimental viral hepatitis in non-human primates is briefly
discussed.
Since we last reviewed the epidemiology of viral hepatitis (1) there have been
a number of advances in our knowledge of the agents responsible for this illness
and a greater appreciation of the diverse modes of transmission by which hepatitis
may be spread. Despite, or in some instances because of, these new observations
in both the laboratory and the field, the conceptual framework within which one
might consider the epidemiology of viral hepatitis has become more rather than
less complex. The available voluminous literature dealing with the Hepatitis B sur-
face antigen (HB,Ag) will not be discussed in detail since this has been the object
of a number of recent reviews. I would prefer to emphasize in these brief remarks
a few selected areas of continuing controversy in which conceptual turnabouts are
likely to occur, and others which have not yet received adequate attention but
will certainly be the subject of future investigations.
AGENTS RESPONSIBLE FOR VIRAL HEPATITIS
The Hepatitis B virus (HBV) is now believed to contain antigenic material in
its core (HB,Ag) as well as on its surface (HB,Ag). Detection of HB,Ag, anti-
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body to this surface antigen (anti-HB), and antibody to the core antigen (anti-
HBC) (2, 3) has permitted specific identification of HBV infections even in the
absence of overt clinical disease. The use of sensitive tests to identify these Hepatitis
B antigens and antibodies has provided a great deal of information about the fre-
quency of infection, range of possible incubation periods, and variations in the clin-
ical manifestations of HBV infections, and has permitted identification of chronic
HB,Ag carriers who may be potential sources of infection.
The recent identification of different virus-like particles with antigenic properties
in the stools of patients with acute Hepatitis A (4, 5, 6), and the demonstration
of seroconversion by immune electron microscopic techniques (5) will provide the
means to gather more information on the epidemiological attributes of this infection
as well.
It seems likely that this newly acquired ability to positively identify both A and
-B infections may shed light on an old problem, the frequency of non-A or B viruses
as the cause of hepatitis. The suggestion that hepatitis may be a complication of
infection with viral agents that usually produce manifestations of disease which
are more prominent than hepatic involvement can now be tested in both sporadic
infections and in epidemiologically related groups of cases. Although CMV, herpes
simplex, Coxsackie, reovirus, and adenovirus (7) as well as other known agents,
have been isolated from occasional patients with clinical hepatitis, their epidemio-
logic importance has not been clear. Whether they are responsible for outbreaks
of hepatitis has been a difficult question to resolve. It seems possible that some
agents may be more important in this respect than others. At least one such agent
has been associated with an outbreak of anicteric hepatitis occurring in a hemodi-
alysis unit. In that episode approximately 25% of dialyzed patients developed the
disease with a mean incubation period estimated to be 25 days, an appropriate
interval for Hepatitis A. Serologic studies provided convincing evidence that EB
virus was the responsible agent (8).
In addition to infection with known viruses, the existence of unidentified hepatitis-
inducing agents may now be approached by means of exclusion. It would appear
likely that hepatitis viruses other than A and B, e.g., C, D or E, may exist and
may be more commonly encountered than was previously believed. The observation
that the incidence of transfusion-associated hepatitis has remained nearly constant
despite implementation of screening of blood donors, albeit imperfectly, for
HB,Ag, during a period in which Type A hepatitis has not increased in frequency
(9) provides circumstantial evidence that much post-transfusion hepatitis is due
neither to A norB, but rather is related to other hepatitis viruses.
Another important area which is now amenable to investigation is concerned
with the existence of different strains of Hepatitis A and B viruses. The identifica-
tion of several subtypes of HB,Ag has provided immunologic evidence for varia-
tions in the Hepatitis B antigens. (10, 11) It has already been demonstrated that
these determinants are related to different subtypes of HBV. Subtype HB,Ag/ayw
is predominant in drug-addict associated viral hepatitis, while HB,Ag/adw is the
predominant subtype in carriers identified among North American and Northern
European blood donors. These antigenic subtypes could have important implica-
tions in both vaccine development and potential efficacy of hyperimmune globulin
for prophylaxis in exposed susceptible populations. In addition, the well known
frequency of multiple episodes of acute viral hepatitis in parenteral drug users may







FIG. 1. Schematic diagram of Hepatitis B virus (HBV) and associated antigens. HBV, repre-
sented here as the 420 A Dane particle, contains a core antigen (HB,Ag) and an immuno-
logically distinct surface antigen (HB,Ag). Although free HB.Ag has not been demonstrated
in the circulation, HBAg is wound on a 200-220 A spherical particle and a tubular form
(of variable length), as well as on HBV.
strains, of Hepatitis B, A, or other hepatitis agents. Until recently, there was scant
sero-epidemiologic evidence to support the concept of immunologic variation in
HAV. However, laboratory studies involving nonhuman primates have now pro-
vided the first evidence of immunologic differentiation in HAV (12). In these stud-
ies direct cross-challenge experiments have indicated the existence of at least two
strains of HAV. Confirmation of these exciting investigations is awaited.
ANTIGENEMIA AND VIREMIA
Much confusion abounds concerning the possible equation of antigenemia with
viremia or infectivity. HB,Ag is a marker of HBV but it is by no means certain
that the presence of HB,Ag indicates that HBV is present at the same time. That
is, it is not clear that de novo synthesis of the virion of Hepatitis B occurs in parallel
with the synthesis of antigenic subunits of the outer viral coat. In fact, there is
little reason to believe that these events are synchronous. Nonparallel production
of viral antigens and infectious virus has been described following inoculation into
human amnion cells of the infectious canine hapatitis virus (13). It would appear
that the HB,Ag is the coat material of the true Hepatitis B virion. Although
HB,Ag may be released from infected cells concurrently with infectious particles
early in the course of infection, host or viral factors which determine or may modify
the sequence of production and release are not presently understood.
It is not yet known whether infectious virions are released constantly, intermit-
tently, or rarely, if at all, in individuals recognized to be chronic carriers of HB,Ag.
This issue is extremely important not only to virologists and immunologists but
also to clinical epidemiologists, hepatologists, and practitioners who are concerned
with the risks of exposure to chronic or transient carriers of HB,Ag.
Of specific interest is the potential risk of Hepatitis B infection following expo-
sure by accidental tissue-penetration with equipment contaminated with blood or
blood products containing HB,Ag. Two nationwide cooperative trials (14, 15)
designed to evaluate the efficacy of high titer anti-HB, gamma globulin in such
situations are currently underway. Although neither code has yet been broken a
most striking feature in both studies has been the very low attack rate of icteric
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or anicteric hepatitis among exposed subjects. The demonstration of HB,Ag in
heat-treated human serum albumin preparations (16) is similarly of interest since
this product is not known to have transmitted hepatitis. These observations provide
circumstantial support for the notion that the presence of HB,Ag does not neces-
sarily signal the existence in the same material of infective doses of HBV.
It might be appropriate, at this point, to raise some cautionary questions con-
cerning trials in which immune serum globulin containing high titers of anti-HBs
is being administered. Although preliminary studies have suggested that such ma-
terial may be effective, (17, 18) the titer of anti-HB, may not be the best indicator
of whether a specific preparation contains that immunoglobulin which will effec-
tively neutralize infectious virus. A number of trials of so-called conventional im-
mune serum globulin have provided conflicting evidence of efficacy in the pre-
vention or modification of transfusion-associated hepatitis (7). Methodological
differences, such as lack of randomization, unblinded observations, and variable fol-
low-up techniques, may account for some of the variability in reported effectiveness.
However, inherent differences in the immune serum globulin employed in these
trials may be even more crucial. When some of these materials were tested recently
for anti-HB, no correlation between titer and reported efficacy could be demon-
strated (19). This observation suggests that effective neutralizing antibody may
not have been measured. Clearly, further information must be sought for other
specific antibodies, e.g., anti-HBc, and their relationship to antibodies present in
the materials used in therapeutic trials. The recently demonstrated failure of high
titer anti-HBs to modify fulminant hepatitis due to HBV may be a case in point
(20), although other explanations for its lack of efficacy may be more appropriate
in this situation.
The role of the health worker in the spread of HBV is presently a subject of
intense interest. It is reasonably clear that medical and paramedical personnel are
at higher risk for acquiring viral hepatitis than is the general population, (7, 21,
22). Recognized and unrecognized parenteral exposures, and contact-transmission-
involving asymptomatic or anicteric cases, may be responsible for epidemics and
sporadic cases among health workers, particularly in hemodialysis and transplanta-
tion units where a very high risk of developing hepatitis exists (23). The role of
the health worker in transmitting disease to the general population or to specific
intra-hospital populations, is less well understood. Although a number of instances
have been described in which physicians and dentists have been responsible for
outbreaks in their patients because of faulty sterilization techniques, spread by con-
tact transmission (24) although possible, is more controversial. Recent studies de-
signed to determine the prevalence of HB,Ag in medical workers have not defined
the nature of the risk existing for individuals exposed to such carriers by personal
contact. Since the presence of circulating HBIAg may not necessarily indicate the
presence of infectious virus, it is exasperating to attempt to make intelligent recom-
mendations curtailing the professional activities of documented carriers. Future
studies undoubtedly will be directed to this perplexing problem.
NON-PARENTERAL TRANSMISSION OF HEPATITIS B
The implications which have been drawn from equating antigenemia with infec-
tivity also have permeated many of the interpretations of recent investigations of
possible non-parenteral transmission of HBV. The detection of HB,Ag in saliva,
duodenal fluid, urine, semen, and other body fluids has permitted a wide range
of speculation concerning mechanisms of person-to-person transmission of Hepa-
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titis B. The precise role of these materials in the transmission of non-percutaneous
infection remains to be defined, although there is no doubt that nonparenteral trans-
mission can occur. Experimental evidence of successful transmission of Hepatitis
B by the feeding of a large inoculum of infectious serum was demonstrated several
years ago (25). Thus, it seems reasonable that blood or blood contaminated body
fluids can be infective by the oral as well as parenteral route. Observations of high
prevalence rates of HB8Ag and anti-HB, among mentally retarded individuals in
large institutions are also compatible with contact transmission ofHBV, presumably
by fecal-oral spread (18). It should be noted, however, that HB,Ag has not been
found with any consistency in a number of studies directed at examination of fecal
samples from HB,Ag carriers. Unfortunately, available data from institutions for
the mentally retarded do not entirely exclude inapparent percutaneous or parenteral
modes of transmission. Furthermore, as previously indicated, the notion that the
presence of HB,Ag indicates the concomitant presence of HBV remains to be
proved.
The wide spread use of tests for HB8Ag in sporadic cases of hepatitis in adults
living in urban areas of this country has revealed a surprisingly large proportion
of patients with serologic evidence of HBV infection in whom no history of paren-
teral exposure was obtained. (26). Studies of apparently healthy blood donors have
also rovealed the presence in 6-30% of anti-HB. (27). Both pieces of data suggest
that inapparent HBV infection is not uncommon, and that infection had been ac-
quired by contact with asymptomatic infected cases or carriers. Further circumstan-
tial evidence, often cited to support the concept of person-to-person fecal-oral HBV
infection, is the high prevalence rate of HB,Ag and anti-HB, in certain tropical
and subtropical developing populations (28). It has been assumed, because of gen-
erally low levels of hygiene and population crowding in these nations, that HBV
infection has been acquired by fecal-oral spread.
These interpretations are difficult to reconcile with previous observations that
HBV infections are not readily spread from person to person, except by means
of shared needles. It is noteworthy and unfortunate that much of the data on
sporadic hepatitis in adults has been collected during the recent international epi-
demic of parenteral drug abuse, and the value of the absence of parenteral exposure
history must, in at least some instances, be questioned. Whether parenteral spread,
by repeated use of scarification needles, lancets, vaccination equipment, or mecha-
nical transmission by biting insects, is important in developing countries must be
clarified in future studies. The role of minor breaks in the integument and mucous
membranes in the transfer of infection, as distinct from personal contact, requires
further exploration. This mechanism of transmission of Hepatitis B was apparently
responsible, some years ago, for a large outbreak of hepatitis among trackfinders
who suffered multiple lacerations, scratches, and abrasions of their uncovered skin
(29).
In contrast to Hepatitis A, available data have failed to incriminate HBV in
either food or water-borne epidemics of hepatitis. A special case may exist for
shellfish-associated hepatitis which has been described in both epidemic and en-
demic forms (1). The recent recovery of HB,Ag from clams (30) has implications
which may yet alter our concepts of HBV infection through common vehicles.
Whether this is a real epidemiologic entity in the spread of HBV is unknown.
Non-parenteral epidemics of Hepatitis B are most unusual. Only two such con-
tact-associated large outbreaks have been adequately described to date. The first
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of these occurred among U.S. Navy personnel inoculated with plasma in a study
of the efficacy of influenza vaccine (31). 36% of this group developed hcpatitis
after a mean incubation period of 79 days, consistent with Hepatitis B infection.
Three percent of uninoculated personnel also contracted hepatitis, mainly at the
end of the epidemic in inoculated individuals. Allergic symptoms, now recognized
as probably related to the formation and deposition of immune complexes of
HB,Ag and anti-HBs, occurred with equal frequency in both inoculated and unin-
oculated hepatitis cases. The exact mode of transmission of Hepatitis B from inocu-
lated to uninoculated cases was not defined in this outbreak but contact spread
was postulated. The second epidemic of Hepatitis B attributed to person-to-person
transmission occurred in a region of Costa Rica with a high background prevalence
rate of HB,Ag (32). The occurrence of an outbreak of Hepatitis A some 3 years
later provided an opportunity to compare and contrast these two episodes. In the
outbreak attributed to HBV all age groups were affected, the disease spread rather
slowly, and the secondary attack rate was very low. In contrast, in the epidemic
attributed to Hepatitis A cases were concentrated in children, the disease appeared
to have been rapidly disseminated within the community, and secondary attack
rates were about 4 times greater than in the Hepatitis B outbreak.
Although the existence of these two contact-associated epidemics of Hepatitis
B cannot be dismissed, the frequency of person-to-person transmission of HBV
and the precise means of spread remain ill defined in general populations. A number
of specific questions have not yet been answered. For example, is the risk of ac-
quiring HBV infection confined to contacts of carriers or to those exposed to
acutely infected individuals? Are skin lesions both a site of entry and exit of virus?
What is the role of shared razors, toothbrushes, drinking glasses, etc.? Is there
a real risk of venereal transmission? The role of the latter mode of transmission
has been re-evaluated recently in view of some new observations in selected popula-
tions. A higher prevalence rate has been found among some homosexual groups
than in the general population (33). Furthermore, in a study of secondary attack
rates of HBV infection among household contacts of hemodialysis patients, marital
partners were affected 14 times more frequently than children and non-spouse
adults (34). Although sexual transmission may explain these differential rates, it
is also possible that spouses were more intimately exposed to blood in dialysis
procedures than were other household members. The recent failure to demonstrate
a difference in HBV infection rates in female prostitutes compared to nuns (35)
also suggests that venereal transmission may not be as important as has been sug-
gested by some investigators. Further investigation of the venereal mode of trans-
mission is required.
HEPATITIS VACCINES
Although we are undoubtedly closer now to vaccine development for the pre-
vention of both Hepatitis A and B than ever before, a number of formidable prob-
lems remain before this goal can be realized. Preliminary trials of heat-inactivated
preparations of serum containing HB,Ag have provided evidence of protection
in limited studies (36, 37). Whether this technique will prove reproducible and
efficacious in larger trials is not yet known. The inability to propagate and isolate
either virus A or B in tissue culture systems to date suggests that much work will
be required before the development of an attentuated live virus vaccine is feasible.
Once these agents are grown in tissue culture systems, it is still likely that at least
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5 years and probably 10 years will elapse before a specific hepatitis vaccine is
commerically available.
EXPERIMENTAL VIRAL HEPATITIS
One of the most important developments in viral hepatitis research has been
the transmission of both Hepatitis A and B to non-human primates. As recently
outlined (38), exploitation of these experimental models should provide new in-
formation concerning 1) host factors which determine the localization of hepatitis
viruses in the liver, 2) biochemical pathology of viral liver disease, 3) modification
of the response to infection by immunological, humoral, and genetic factors, 4)
the potential role of antiviral chemotherapy in hepatitis, and 5) the role of immune
mechanisms in recovery from or perpetuation of viral induced liver disease. These
areas will be fertile grounds for new investigatons.
CONCLUSION
One may conclude by noting that exciting information has become available in
recent years and that knowledge of viral hepatitis will certainly continue to expand.
Although a number of challenges lie ahead, the complexities of the virology and
epidemiology of viral hepatitis will eventually be unraveled and there will ultimately
be no necessity for frequent revisions of the conceptual framework within which
we attempt to understand this group of diseases.
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